To explore the underlying mechanisms that control psoralen-mediated protection against radiation-induced osteoporosis in vivo, a specific chemical inhibitor of NRF2 (ML385, 30 mg/Kg) was intraperitoneally injected 1 h before psoralen treatment. The gene discussed is NFE2L2; the disease is osteoporosis.